Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR5 | P51681 | 20/20 | 0.78 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.77 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.77 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5612182 | 0.99 | CCR5 (0.79) | CCR5CYP3A4CYP2C9CYP2D6 | |
| SCHEMBL5350799 | 0.92 | CCR5 (0.82) | CCR5CYP3A4CYP2C9 | |
| SCHEMBL5350688 | 0.92 | CCR5 (0.79) | CCR5CYP3A4CYP2C9CYP2D6 | |
| SCHEMBL6013196 | 0.91 | CCR5 (0.85) | CCR5CYP3A4CYP2C9CYP2D6 | |
| Hydrochloric Acid SCHEMBL5347701 | 0.91 | CCR5 (0.82) | CCR5CYP3A4CYP2C9CYP2D6 | |
| SCHEMBL5340117 | 0.91 | CCR5 (0.85) | CCR5CYP3A4CYP2C9CYP2D6 | |
| SCHEMBL5343750 | 0.91 | CCR5 (0.74) | CCR5CYP3A4CYP2C9CYP2D6 | |
| Hydrochloric Acid SCHEMBL5339308 | 0.91 | CCR5 (0.80) | CCR5CYP3A4CYP2C9CYP2D6 | |
| Hydrochloric Acid SCHEMBL5612845 | 0.91 | CCR5 (0.85) | CCR5CYP3A4CYP2C9CYP2D6 | |
| Hydrochloric Acid SCHEMBL5342955 | 0.91 | CCR5 (0.85) | CCR5CYP3A4CYP2C9CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7119091-B2 | Triazaspiro[5.5]undecane derivatives and pharmaceutical compositions comprising thereof, as an active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-10-10 | — | — | US | claimed |
| EP-1236726-B1 | TRIAZASPIRO 5.5]UNDECANE DERIVATIVES AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO (JP) | 2004-12-01 | — | — | EP | claimed |
| US-20040097511-A1 | Triazaspiro[5.5]undecane derivatives and drugs containing the same as the active ingredient | PANASONIC CORPORATION (JP) | 2004-05-20 | — | — | US | claimed |
| EP-1236726-A1 | TRIAZASPIRO 5.5]UNDECANE DERIVATIVES AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2002-09-04 | — | — | EP | claimed |
| US-7285552-B2 | Drugs containing triazaspiro[5.5]undecane derivatives as the active ingredient | ONO PHARMACEUTICALS CO., LTD. (JP) | 2007-10-23 | — | — | US | disclosed |
| US-7285552-B2 | Drugs containing triazaspiro[5.5]undecane derivatives as the active ingredient | ONO PHARMACEUTICALS CO., LTD. (JP) | 2007-10-23 | — | — | US | disclosed |
| EP-1378509-A1 | DRUGS CONTAINING TRIAZASPIRO 5.5]UNDECANE DERIVATIVES AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-01-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040097511-A1 | Triazaspiro[5.5]undecane derivatives and drugs containing the same as the active ingredient | CXCR5, CCL11, ACKR3 | CCR5 5/4885CYP3A4 1204/4885CYP2C9 692/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.